Cullinan Therapeutics, Inc. (CGEM)
| Market Cap | 1.37B +275.1% |
| Revenue (ttm) | n/a |
| Net Income | -208.34M |
| EPS | -3.47 |
| Shares Out | 64.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 763,872 |
| Open | 21.45 |
| Previous Close | 21.08 |
| Day's Range | 20.98 - 21.79 |
| 52-Week Range | 5.68 - 23.19 |
| Beta | 0.02 |
| Analysts | Strong Buy |
| Price Target | 33.55 (+57.14%) |
| Earnings Date | Nov 5, 2026 |
About CGEM
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysp... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for CGEM stock is "Strong Buy." The 12-month stock price target is $33.55, which is an increase of 57.14% from the latest price.
News
Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
CAMBRIDGE, Mass., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, ...
Cullinan Therapeutics price target raised to $40 from $39 at BTIG
BTIG raised the firm’s price target on Cullinan Therapeutics (CGEM) to $40 from $39 and keeps a Buy rating on the shares after the company presented Phase 3 REZILIENT3 data…
Cullinan Therapeutics Transcript: Study result
The phase III REZILIENT3 trial showed zipalertinib plus chemotherapy significantly improved progression-free survival and response rates in first-line EGFR exon 20 insertion mutation NSCLC, with strong efficacy in brain metastases and a manageable safety profile, supporting its potential as a new standard of care and substantial market adoption.
Cullinan Therapeutics Press release: Study result
Cullinan Therapeutics issued a press release on September 14, 2026, disclosing material business information to investors.
Cullinan Therapeutics Slides: Study result
Cullinan Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 14, 2026.
Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modi...
Cullinan, Taiho announce Phase 3 REZILIENT3 trial met primary endpoint
Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics (CGEM) announced results from the Phase 3 REZILIENT3 trial evaluating zipalertinib plus chemotherapy versus chemotherapy alone in the fi...
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
PRINCETON, N.J. & TOKYO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from the Phase...
Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
Results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC to be presented in Presidential Symposiu...
Cullinan, Taiho say results of Phase 3 trial selected for presentation
Taiho Oncology and Cullinan Therapeutics (CGEM) announced that results from the planned interim analysis of the Phase 3 REZILIENT3 trial have been selected for presentation in the Presidential Symposi...
Taiho, Cullinan Therapeutics study demonstrates statistically significant PFS
The company states: “Taiho Oncology Taiho Pharmaceutical Co, and Cullinan Therapeutics (CGEM) announced that the REZILIENT3 trial, a global Phase 3 clinical trial evaluating the combination of zipaler...
Cullinan Therapeutics price target raised to $47 from $46 at Clear Street
Clear Street analyst Kaveri Pohlman raised the firm’s price target on Cullinan Therapeutics (CGEM) to $47 from $46 and keeps a Buy rating on the shares after the Phase 3…
Cullinan Therapeutics reports Q2 EPS (81c), consensus (85c)
“At our recent Immunology Day event, we shared compelling initial clinical data for CLN-978 and velinotamig, two T cell engagers with potential to achieve immune reset and transform outcomes for…
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
CLN-978 (CD19 TCE) multi-dose regimen data in RA in Q3 2026 and SLE in Q4 2026; Phase 2 expansion studies to begin early 2027
Cullinan Therapeutics Quarterly report: Q2 2026
Cullinan Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Cullinan Therapeutics Earnings release: Q2 2026
Cullinan Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Cullinan Therapeutics price target raised to $39 from $38 at BTIG
BTIG raised the firm’s price target on Cullinan Therapeutics (CGEM) to $39 from $38 and keeps a Buy rating on the shares. The firm notes that CLN-049 is advancing to…
Cullinan Therapeutics announces End-of-Phase 1 meeting for CLN-049 with FDA
Cullinan Therapeutics (CGEM) announced feedback from the FDA following an End-of-Phase 1 meeting for CLN-049, a FLT3xCD3 T cell engager being evaluated in patients with acute myeloid leukemia. The EOP...
Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML
CAMBRIDGE, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, d...
Cullinan Therapeutics management to meet with BTIG
Biotechnology Analyst Harrison holds a group dinner meeting with management in New York on July 21 at 5:30 pm hosted by BTIG.
Cullinan Therapeutics price target raised to $46 from $33 at Clear Street
Clear Street raised the firm’s price target on Cullinan Therapeutics (CGEM) to $46 from $33 and keeps a Buy rating on the shares. CLN-978’s initial Phase 1 data, including remissions…
Cullinan Therapeutics Transcript: Immunology Day 2026
CLN-978 and velinotamig, two T-cell engagers, showed strong efficacy and safety in refractory autoimmune diseases, achieving deep B-cell and antibody depletion and clinical remission. Multi-dose and tissue data support immune reset, with phase II studies and regulatory milestones planned for 2027.
Cullinan Therapeutics Slides: FY 2026
Cullinan Therapeutics has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 10, 2026.
Cullinan Therapeutics Press release: FY 2026
Cullinan Therapeutics issued a press release on June 10, 2026, disclosing material business information to investors.
Cullinan Therapeutics reports CLN-978, velinotamig data
Cullinan Therapeutics (CGEM) reported clinical data and outlined global clinical development plans for CLN-978, a CD19xCD3 T cell engager, and velinotamig, a BCMAxCD3 T cell engager. New multi-dose da...